Showing results (1421-1430 of 1,566) with videos related to

Sort By:
Pageof 157
ESMO Open|January 4, 2025
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trialB Pellegrino, E D Capoluongo, M Bagnoli, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
YAP-Driven Oral Epithelial Stem Cell Malignant Reprogramming at Single Cell ResolutionFarhoud Faraji, Sydney I Ramirez, Lauren Clubb, et al.
Cancer Discovery|June 15, 2019
Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated FibroblastsEla Elyada, Mohan Bolisetty, Pasquale Laise, et al.
Cancers|April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer PatientsCrescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Rafal Dziadziuszko, Shunichi Sugawara, et al.
World Journal of Urology|May 22, 2024
Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patientsSimone Morra, Reha-Baris Incesu, Lukas Scheipner, et al.
The Journal of Clinical Endocrinology and Metabolism|September 22, 2005
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancerMingzhao Xing, William H Westra, Ralph P Tufano, et al.
Cancer Cell|November 3, 2023
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancerJessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2021
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L TrialD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Nature Cancer|December 30, 2022
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancerTizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, et al.
Pageof 157